Abstract CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated) adaptive immune systems constitute a bacterial defence against invading nucleic acids derived from bacteriophages or plasmids. This prokaryotic system was adapted in molecular biology and became one of the most powerful and versatile platforms for genome engineering. CRISPR/Cas9 is a simple and rapid tool which enables the efficient modification of endogenous genes in various species and cell types. Moreover, a modified version of the CRISPR/Cas9 system with transcriptional repressors or activators allows robust transcription repression or activation of target genes. The simplicity of CRISPR/Cas9 has resulted in the widespread use of this technology in many fields, including basic research, biotechnology and biomedicine.

Keywords CRISPR/Cas9 · Genome editing · Off-target effect · Guide RNA

Introduction

Bacteria and archaea have devised various defence strategies that allow them to survive exposure to foreign nucleic acids such as viral genomes and plasmids. These resistance mechanisms include: prevention of phage adsorption, blocking of phage DNA injection, phage abortive infection systems and restriction modification systems (Chibani-Chennoufi et al. 2004; Chopin et al. 2005; Forde and Fitzgerald 1999). This defensive repertoire has been expanded by the recent discovery of the adaptive microbial immune system, based on clustered regularly interspaced short palindromic repeats (CRISPR) and Cas (CRISPR-associated) genes. CRISPRs were first found in the *Escherichia coli* genome in 1987, when Ishino et al. (1987) discovered loci containing repeat sequences with an unknown function downstream from the *iap* gene. The CRISPR loci are observed in nearly 40 % genomes of sequenced bacteria and nearly 90 % genomes of sequenced archaea (Sorek et al. 2008). Barrangou et al. (2007) demonstrated that CRISPR, together with the associated Cas genes, form an adaptive immunity, which provides resistance against bacteriophage infection. The CRISPR/Cas system is a highly adaptive and heritable resistance mechanism that incorporates short sequences from viruses and other mobile genetic elements into the host’s CRISPR locus to be transcribed and processed into small RNAs that guide the destruction of invading nucleic acids (Charpentier and Marraffini 2014).

Functioning of the Type II CRISPR/Cas System in Bacteria

CRISPR/Cas systems of bacterial adaptive immunity are classified into three types according to the differences between the sequence and the structure of Cas proteins. The mechanisms of immunity in types I and III CRISPR/Cas systems are quite complex and are not applied in genome engineering. The simplest among CRISPR/Cas systems is type II, which to interfere with invading genetic elements requires only a single multi-functional Cas9

Magdalena Hryhorowicz1 · Daniel Lipiński1 · Joanna Zeyland1 · Ryszard Słomski1,2

1 Department of Biochemistry and Biotechnology, Poznań University of Life Sciences, Poznań, Poland
2 Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland
protein (Makarova et al. 2011). In the endogenous
CRISPR/Cas9 system three components are necessary for
target cutting: Cas9 protein, CRISPR RNA (crRNA) and
tenasactivant crRNA (tracrRNA), which contributes to
crRNA maturation and the formation of the Cas9 complex.
The type II CRISPR/Cas system comprises three stages:
first, acquisition of CRISPRs; second, crRNA biogenesis;
third, interference with invading DNA (Fig. 1). In the
acquisition stage, the invading phage DNA is processed by
a Cas nuclease into small DNA fragments, called proto-
spacer sequences, and then incorporated into the CRISPR
locus of the bacterial genome as a new spacer (Wiedenheft
et al. 2012). Each CRISPR array encodes acquired spacers
that are separated by repeat sequences. The selection of
protospacers depends in part on the specific recognition of
protoscaler adjacent motifs (PAMs) present within the
viral genome. However, protoscaler sequences incorpo-
rated into the CRISPR locus do not contain PAM sites
(Mojica et al. 2009). The identity of the PAM sequence
depends on the species of the Cas9 protein (for example:
5’TGG-3’ PAM in Streptococcus pyogenes, 5’-NGGNG-3’
PAM in Streptococcus thermophilus and 5’NNNNGATT-3’
PAM from Neisseria meningitides) (Cho et al. 2013; Hou
et al. 2013; Karvelis et al. 2013). Subsequently, in the
biogenesis step, the CRISPR locus is transcribed into a
long precursor CRISPR RNA (pre-crRNA). TracrRNA
hybridizes to the repeat sequences of the pre-crRNA and
then endogenous RNase III cleaves this complex, yielding
mature crRNAs, each containing one spacer and partial
repeat sequence (Deltcheva et al. 2011; Pougach et al.
2010). Finally, in the interference step, mature crRNA
guides Cas9 protein to the complementary foreign nucleic
acids, triggering degradation of the DNA sequences of
invading phages (Garneau et al. 2010; Marraffini and
Sontheimer 2008). The Cas9 protein contains HNH (named
for characteristic histidine and asparagine residues) and
RuvC (named for an E. coli protein involved in DNA
repair) nuclease domains, which cleave the DNA comple-
mentary strand and the non-complementary strand,
respectively (Jinek et al. 2012). This endonuclease cleaves
the viral genome by introducing double-strand breaks
(DSB) 3 bp upstream of the appropriate PAM. The PAM
sequence is crucial for the interference stage because it
enables one to distinguish between the invading foreign
DNA and the CRISPR loci in the host genome, which do
not contain PAM (Shah et al. 2013).

![Fig. 1 The three stages of the CRISPR/Cas bacterial adaptive immune system: acquisition, crRNA biogenesis and interference of viral DNA](image-url)
Exploiting CRISPR/Cas9 Systems for Genome Engineering

The guide sequence within CRISPR spacers typically corresponds to foreign viral genomes constituting the form of the acquired immunity of bacteria, but can easily be substituted by a sequence of interest to target the Cas9 protein. In 2012, two research groups published findings stating that purified Cas9, derived from Streptococcus thermophilus or Streptococcus pyogenes, can be guided by crRNAs to cleave target DNA in vitro (Gasiunas et al. 2012; Jinek et al. 2012). Moreover, the RNA components of the CRISPR/Cas9 system can be used separately as crRNA containing the targeting guide sequence and constant tracrRNA molecules, or as single guide RNA (sgRNA) chimera, consisting of a fusion of a crRNA and a tracrRNA facilitates rapid implementation of the CRISPR/Cas9 system for genome engineering. Cas9 target recognition requires both the PAM sequence in the target DNA and RNA–DNA complementarity base pairing between the 20-nt guide RNA sequence and the complementary target DNA sequence (Jinek et al. 2012). Cas9-generated site-specific DNA double-strand breaks induce endogenous cellular DNA repair processes, which can be exploited to engineer the genome. DSBs are generally repaired by one of two pathways, homologous directed repair (HDR) if the homologous template is available or otherwise by nonhomologous end joining (NHEJ). NHEJ is an error-prone process that can rapidly ligate the broken ends but generate small insertions and deletions (indels) at targeted sites, which often result in the function of target genes being disrupted or abolished. Alternatively, DSB may also be repaired via HDR, which is able to recombine exogenous DNA, and can be used to introduce transgenes or precise genome editing (Fig. 2).

Earlier technologies to introduce DSBs, such as zinc-finger nucleases (ZFN) and transcription activator-like effector nucleases (TALEN), are fusions of the nonspecific DNA cleavage domain from the FokI restriction endonuclease and sequence-specific DNA binding domains derived from zinc-finger and TALE proteins. ZFNs and TALENs require recoding of proteins for each new target site, which is time consuming and very expensive. In contrast, CRISPR/Cas9 to target a new site only requires a suitable sgRNA to be designed, because the Cas9 protein remains the same in all cases. Moreover, the expression of Cas9 and multiple guide RNAs can be used for simultaneous editing of several target sites in the mammalian genome (Cong et al. 2013). The fact is that CRISPR/Cas9 technology is easy to design and produce, is highly efficient and inexpensive. Exemplary protocols for preparation of CRISPR/Cas reagent to create genetically modified mouse were described by Harms et al. (2014).

Non-nuclease Uses of Cas9 Protein

The CRISPR/Cas9 system is a powerful tool for genome modification but can also be used to regulate the expression of endogenous genes (Qi et al. 2013). Catalytically dead Cas9 (dCas9) protein with inactive RuvC and HNH nuclease domains retains the ability to bind to target DNA (complementary to the sgRNA) and causes repression of the target gene by a steric block that stops transcript elongation by RNA polymerase. This CRISPR-based interference (CRISPRi) is a similar approach to RNA interference (RNAi) with the difference that CRISPRi regulates gene expression on the transcriptional level, while RNAi on the mRNA level. Moreover, dCas9 protein can be fused to a transcriptional activator (e.g., VP64) or to transcriptional repressors (e.g., Krüppel associated box). These dCas9 fusion proteins are targeted to the indicated promoter region, resulting in transcription repression or activation of target genes (Gilbert et al. 2013; Maeder et al. 2013). Significantly, this does not permanently modify the genome because dCas9-mediated gene activation or repression is reversible. The fusion of activator or repressor to dCas9 can be used for studying of specific genes and identify the functions of new genes (Konermann et al. 2015). It has been also demonstrated that an EGFP-tagged dCas9 protein can be used to locate and visualize specific genomic loci in living cells (Chen et al. 2013).

Off-Target Effects

The CRISPR/Cas9 system enables permanent genome modification and, therefore, its off-target effects, which are alterations occurring outside the targeted locus, should be controlled. The off-target sites are identical or highly homologous to the target DNA sequence and can be recognized by Cas9 protein, which tolerates some mismatches between the sgRNA and the target DNA (Hsu et al. 2013). In general, the mismatches closer to the 5’ end of the 20 nt targeting region of the gRNA are better tolerated than mismatches close to the PAM at the 3’ end. Interestingly, some studies suggest that even Cas9 which is able to bind to off-target sites cleaves only some of them (Wu et al. 2014). Indel mutation at the off-target sites can be detected by searching the sequences with high similarity to the target locus and genome-wide identification of Cas9 cleavage profile by GUIDE-seq or by whole genome sequencing (Smith et al. 2014; Tsai et al. 2014b).

Although there are some studies demonstrated low incidence of off-target mutations in Cas9-modified mice and Cas9-engineered human pluripotent stem cells (Iyer et al. 2015; Veres et al. 2014), various approaches have
been explored to reduce the off-target effects. First, when gRNAs are designed, it is recommended to select those target sites predicted to have the fewest off-target sequences. Several online tools are available for facilitating the identification of suitable guide sequences (e.g., http://crisp.mit.edu/) and that web-based software supplies the specificity score of off-target effects. Generally, use of a high-score guide yields higher target specificity with a lower chance of off-target mutagenesis. Additionally, it has recently been suggested that off-target effects can be reduced using guide RNA truncated by 2–3 nt at the 5' end. These truncated gRNAs may increase specificity because a shorter sgRNA sequence has a decreased mismatch tolerance, although this manipulation results in a reduction in the absolute efficiency of on-target genome editing (Fu et al. 2014).

Another way of limiting off-target endonuclease effect is to use a Cas9 nickase mutant and pairs of gRNAs to introduce targeted double-strand breaks (Cho et al. 2014; Shen et al. 2014). A mutant form of Cas9 introduces a single-stranded break (called a nick) by catalytically inactivating the RuvC or HNH nuclease domains (Jinek et al. 2012). In this method, pairs of Cas9 nickases are targeted to generate two nicks close to each other on opposite strands of the genomic target DNA, which can be the equivalent of a DSB. The double nicking system can significantly increase specificity because off-target single nick should be repaired immediately without any undesirable mutation. Furthermore, the chance that two nicks occur together in the same arrangement like target sites elsewhere in the genome and generate DSB is extremely small. Importantly, using Cas9 nickases significantly reduces off-target mutagenesis but at the expense of lower efficiency (Li et al. 2014).

Similarly, fusions of catalytically inactive Cas9 (dCas9) with FokI nuclease domain can also improve DNA cleavage specificity (Guilinger et al. 2014; Tsai et al. 2014a). In this approach, designing two gRNAs, which are bound in close proximity to two unique target sites, are necessary. Binding dCas9-FokI fusion proteins to the target sequences and dimerization of pair FokI domains is required to generate a DSB. This system is regarded to have even lower off-target effects than dual nickase because monomeric FokI nuclease domains are not catalytically competent (Guilinger et al. 2014).

The dosage of CRISPR/Cas9 components is also an important factor affecting off-target mutagenesis and should be carefully monitored. As previously mentioned, Cas9 can tolerate some mismatches within the target site leading to off-target activity. It has been proven that mismatches appear to be better tolerated when Cas9 occurs in high concentrations. Therefore, decreasing the amount of Cas9 in the CRISPR/Cas9 delivery system substantially reduces off-target effects. Unfortunately, the efficiency of on-target cleavage is also at a lower level (Hsu et al. 2013).

The latest approaches to decrease off-target effects of CRISPR/Cas9 involve new Cas9 variants: eSpCas9 and SpCas9-HF1. Slaymaker et al. (2016) demonstrated, through structure-guided protein engineering, that neutralization of positive charges in the HNH/RuvC groove can
Application of CRISPR/Cas9 System

The type II CRISPR/Cas system has been rapidly and widely utilized to target genome modifications in various species and cell types, including plants (Jiang et al. 2013), insects (Bassett et al. 2013), mice (Seruggia et al. 2015), rabbits (Honda et al. 2015), pigs (Whitworth et al. 2014), monkeys (Niu et al. 2014) and human cells (Liang et al. 2015). CRISPR/Cas9 is an efficient system for genome engineering of animals, which gives unlimited possibilities for xenotransplantation, regenerative medicine and using animals as models for studying of human diseases. Genetically modified large animal models are of increasing significance in biomedical research. To obtain large transgenic animals with CRISPR/Cas9 system, plasmids expressing Cas9 and properly designed sgRNA can be easily introduced into the cells by transfection and used in somatic cell nuclear transfer (Ni et al. 2014). Another route relied on in vitro transcription of Cas9 and sgRNA and direct injection of Cas9 mRNA and sgRNA into fertilized zygotes (Whitworth et al. 2014). CRISPR/Cas9 system enables multiplex genome editing. Wang et al. (2013) demonstrated that CRISPR/Cas allowed the simultaneous disruption of five genes in mouse embryonic stem cells with high efficiency. Moreover, the application of CRISPR/Cas9 multiplexability to inactivate porcine endogenous retrovirus (PERVs) in a swine kidney epithelial cell line has recently been described. In this study, two sgRNAs were designed to disrupt 62 copies of the PERV pol gene critical for retroviral activity. The scientists noted a >1000-fold reduction in PERV transmission to human cells, which suggests the possibility to inactivate PERVs for clinical application of porcine-to-human xenotransplantation (Yang et al. 2015).

Mutagenic chain reaction (MCR), described by Gantz and Bier, is another example of application of the CRISPR Cas9 system. MCR based on the CRISPR/Cas9 system is used for generating autocatalytic mutations to generate homozygous loss-of-function mutations (Gantz and Bier 2015). The authors developed a technology to convert a Drosophila heterozygous recessive mutation into homozygosity. MCR’s construct consist Cas9 gene and gRNA which are flanked by two homology arms targeting the genomic sequences to be cut. Usually, mutations carried on one of a pair of chromosomes are inherited by only half the offspring. MCR system allows a mutation on one chromosome to copy itself in both somatic and germline cells “gene drive”, which results in that almost all offspring will inherit the change. MCR could be used to eliminate diseases such as malaria, yellow fever and others by altering insect species to eradicate invasive species and to pave the way toward sustainable agriculture by reversing pesticide and herbicide resistance. Despite the fact that this technology can be very useful, there are concerns about the risks associated with release of MCR organisms into the environment because modifying a whole population, or eliminating it altogether, could have unknown consequences for an ecosystem.

The CRISPR/Cas9 system can also be used as a therapeutic technology for treating genetic disorders such as Duchenne muscular dystrophy (DMD) by correcting the dystrophin gene mutation (Long et al. 2014) or cystic fibrosis by repairing the mutation in the CFTR gene (Schwank et al. 2013). DMD is caused by mutation in the dystrophin gene, which consists of 79 exons. Removing one or more exons from the mutated transcript by CRISPR/Cas9 system allowed for production of truncated, but still functional dystrophin protein in a mouse model of muscular dystrophy (Tabebardbar et al. 2016). Moreover, restored dystrophin protein expression was obtained by exon skipping, frameshifting, and exon knock-in in DMD-patient-derived induced pluripotent stem cells. The exon knock-in was the most effective approach and resulted in restoration of the full-length dystrophin protein (Li et al. 2015).

Additionally, the CRISPR/Cas9 system has therapeutic potential for preventing coronary heart disease. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein expressed in liver cells. It has been shown that spontaneous loss-of-function PCSK9 mutations reduced low-density lipoprotein cholesterol levels (Cohen et al. 2005). Thus, CRISPR/Cas9 technology was used for generating a knockout of PCSK9 gene in mice. Genome editing with CRISPR/Cas9 successfully and efficiently disrupted the PCSK9 gene in vivo, leading to reduced plasma cholesterol.
levels. It may have therapeutic potential for the prevention of cardiovascular disease in humans (Ding et al. 2014). Another example of the application of the CRISPR/Cas9 system is in the treatment of viral infections. For example, CRISPR/Cas9 can efficiently knockout the CCR5 (CC chemokine receptor 5) gene to prevent HIV-1 integration (Ye et al. 2014). In turn, another group demonstrated that the CRISPR system targeted at the surface antigen (HBsAg)-encoding region of HBV efficiently produced mutations in HBV DNA. This resulted in inhibition of HBV replication and expression, and can be used as a new therapeutic strategy for HBV infection (Zhen et al. 2015).

Conclusion

In August last year, the CRISPR/Cas as an Adaptive Bacterial Immune System on Its Way to Become a Game Changer in Genetic Engineering was one of the topics of the Biological Weapons Convention Meeting of Experts of United Nations, Geneva. The reason was the emergence of reports about the possibilities of dual use of this technology. Presentation concerning CRISPR/Cas9 technology was met with great interest among the delegations of individual countries but also raised many concerns. Unease was raised by articles pointing at the possibility of using this technology to induce cancer in mice to create model for human lung cancer (Maddalo et al. 2014). Components of CRISPR/Cas9 delivered to mice by inhalation using adenovirus easily results in the formation of lung tumours in these animals already after a few weeks. Greater concern is how easily and quickly one can induce tumours in different tissues and organisms using this technology and what kind of consequences will be associated with the improper designing or using of CRISPR/Cas9 system. Some researchers even call for an end to work using CRISPR/Cas9 technology but the experience of authors, in particular a leader of the team (prof. R. Słomski), shows that in the history of genome engineering in 1974 Paul Berg and other scientists in the field of recombinant DNA drafted a letter calling upon “scientists throughout the world” to suspend certain types of studies until hazards could be assessed (Berg et al. 1974). However, despite a number of concerns they have failed to stop them with the perspective of time contributed to new discoveries and achievements in the field of biology, agriculture and medicine.

The CRISPR/Cas9 is an efficient, cheap and easy-to-use tool for a genome editing, which is rapidly being applied to many fields, including generation of the animal models, functional genomic screening and correction of genetic disorders. However, this technology must be used carefully. Planning CRISPR/Cas experiments, precise design of gRNA, choosing the best variant of Cas9 and genome-wide searching of potential off-target sites should be taken into account. Scientists should think cautiously about how they are going to use that powerful technology. Only then, it will be possible to use the CRISPR/Cas9 system safely.

Acknowledgments This work was supported by The National Centre for Research and Development (Grant No. INNOMED/I/17/NCBR/2014) in the framework of the “INNOMED” programme titled “Development of an innovative technology using transgenic porcine tissues for biomedical purposes”. Acronym: “MEDPIG”.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

Barrangou R, Fremaux C, Boyaval P et al (2007) CRISPR provides acquired resistance against viruses in prokaryotes. Science 315:1709–1712
Bassett AR, Tibbit C, Ponting CP et al (2013) Highly efficient targeted mutagenesis of Drosophila with the CRISPR/Cas9 system. Cell Rep 4:220–228
Berg P, Baltimore D, Boyer HW et al (1974) Letter: potential biohazards of recombinant DNA molecules. Science 185:303
Charpentier E, Marraffini LA (2014) Harnessing CRISPR-Cas9 immunity for genetic engineering. Curr Opin Microbiol 19:114–119
Chen B, Gilbert LA, Cimini BA et al (2013) Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell 155:1479–1491
Chibani-Chennoufi S, Bruttin A, Dillmann ML et al (2004) Phage-host interaction: an ecological perspective. J Bacteriol 186:3677–3686
Cho SW, Kim S, Kim JM et al (2013) Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 31:230–232
Cho SW, Kim S, Kim Y et al (2014) Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res 24:132–141
Chopin MC, Chopin A, Bidnenko E (2005) Phage abortive infection in lactococci: variations on a theme. Curr Opin Microbiol 8:473–479
Cohen J, Pertsemlidis A, Kotsowki IK et al (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37:161–165
Cong L, Ran FA, Cox D et al (2013) Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–823
Delcheva E, Chylinski K, Sharma CM et al (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471:602–607
Ding Q, Strong A, Patel KM et al (2014) Permanent alteration of PCSK9 with in vivo CRISPR/Cas9 genome editing. Circ Res 115:488–492
Forde A, Fitzgerald GF (1999) Bacteriophage defence systems in lactic acid bacteria. Antonie Van Leeuwenhoek 76:89–113
Fu Y, Sander JD, Reyon D et al (2014) Improving CRISPR-Cas9 nuclease specificity using truncated guide RNAs. Nat Biotechnol 32:279–284
Gantz VM, Bier E (2015) The mutagenic chain reaction: a method for converting heterozygous to homozygous mutations. Science 348:442–444
Gameau JE, Dupuis ME, Villion M et al (2010) The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468:67–71
Gasiunas G, Barrangou R, Horvath P et al (2012) Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci USA 109:E2579–E2586
Gilbert LA, Larson MH, Morsut L et al (2013) CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154:442–451
Guilinger JP, Thompson DB, Liu DR (2014) Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat Biotechnol 32:577–582
Harms DW, Quadros RM, Seruggia D et al (2014) Mouse genome editing using the CRISPR/Cas system. Curr Protoc Hum Genet 83:15.7.1–15.7.27
Honda A, Hirose M, Sankai T et al (2015) Single-step generation of rabbits carrying a targeted allele of the tyrosinase gene using CRISPR/Cas9. Exp Anim 64:31–37
Hou Z, Zhang Y, Propson NE et al (2013) Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc Natl Acad Sci USA 110:15644–15649
Ishino Y, Shinagawa H, Makino K et al (1987) Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol 169:5429–5433
Iyer V, Shen B, Zhang W et al (2015) Off-target mutations are rare in Cas9-modified mice. Nat Methods 12:479
Jiang W, Zhou H, Bi H et al (2013) Demonstration of CRISPR/Cas9/sgRNA-mediated targeted gene modification in Arabidopsis, tobacco, sorghum and rice. Nucleic Acids Res 41:e188
Jinek M, Chylinski K, Fonfara I et al (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337:816–821
Karvelis T, Gasiunas G, Mikysk A et al (2013) crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus. RNA Biol 10:841–851
Kleinsteiver BP, Pattanayak V, Prew MS et al (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529:490–495
Konermann S, Brigham MD, Trevino AE et al (2015) Genome-scale transcriptional activation by an engineered CRISPR/Cas9 complex. Nature 517:583–588
Li K, Wang G, Andersen T et al (2014) Optimization of genome engineering approaches with the CRISPR/Cas9 system. PLoS One 9:e105779
Li HL, Fujimoto N, Sasakawa N et al (2015) Precise correction of the dystrophin gene in duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Reports 4:143–154
Liang P, Xu Y, Zhang X et al (2015) CRISPR/Cas9-mediated gene editing in human tripolarny oocytes. Protein Cell 6:363–372
Long C, McAnally JR, Shelton JM et al (2014) Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA. Science 345:1184–1188
Maddalol D, Manchado E, Concepcion CP et al (2014) In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516:423–427
Maeder ML, Linder SJ, Cascio VM et al (2013) CRISPR RNA-guided activation of endogenous human genes. Nat Methods 10:977–979
Makarova KS, Haft DH, Barrangou R et al (2011) Evolution and classification of the CRISPR-Cas systems. Nat Rev Microbiol 9:467–477
Marraffini LA, Sontheimer EJ (2008) CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. Science 322:1843–1845
Mojica FJ, Díez-Villaseor C, García-Martínez J et al (2009) Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155(Pt 3):733–740
Ni W, Qiao J, Hu S et al (2014) Efficient gene knockout in goats using CRISPR/Cas9 system. PLoS One 9:e106718
Niu Y, Shen B, Cui Y et al (2014) Generation of gene-modified cynomolgous monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. Cell 156:836–843
Pougach K, Semenova E, Bogdanova E et al (2010) Transcription, processing and function of CRISPR cassettes in Escherichia coli. Mol Microbiol 77:1367–1379
Qi LS, Larson MH, Gilbert LA et al (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152:1173–1183
Schwank G, Koo BK, Sasselli V et al (2013) Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 13:653–658
Seruggia D, Fernandez A, Cantero M et al (2015) Functional validation of mouse tyrosinase non-coding regulatory DNA elements by CRISPR-Cas9-mediated mutagenesis. Nucleic Acids Res 43:4855–4867
Shah SA, Erdmann S, Mojica FJ et al (2013) Protospacer recognition motifs: mixed identities and functional diversity. RNA Biol 10:891–899
Shen B, Zhang W, Zhang J et al (2014) Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods 11:399–402
Sluymer MA, Gao L, Zetsche B et al (2016) Rationally engineered Cas9 nucleases with improved specificity. Science 351:84–88
Smith C, Gore A, Yan W et al (2014) Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-mediated gene editing in human iPSCs. Cell Stem Cell 15:12–13
Sorek R, Kunin V, Hagenholtz P (2008) CRISPR—a widespread system that provides acquired resistance against phages in bacteria and archaea. Nat Rev Microbiol 6:181–186
Tabebordbar M, Zhu K, Cheng JK et al (2016) In vivo gene editing in dystrophic muscle and muscle stem cells. Science 351:407–411
Tsai SQ, Wyvekens N, Khayter C et al (2014a) Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat Biotechnol 32:569–576
Tsai SQ, Zheng Z, Nguyen NT et al (2014b) GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol 33:187–197
Wang H, Yang H, Shivalila CS et al (2013) One-step generation of mice carrying mutations in multiple genes by CRISPR-Cas-mediated genome engineering. Cell 153:910–918
Whitworth KM, Lee K, Benne JA et al (2014) Use of the CRISPR/Cas9 system to produce genetically engineered pigs from in vitro-derived oocytes and embryos. Biol Reprod 91:78
Wiedenheft B, Sternberg SH, Doudna JA (2012) RNA-guided genetic silencing systems in bacteria and archaea. Nature 482:331–338

Wu X, Scott DA, Kriz AJ et al (2014) Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol 32:670–676

Yang L, Güell M, Niu D et al (2015) Genome wide inactivation of porcine endogenous retroviruses (PERVs). Science 350:1101–1104

Ye L, Wang J, Beyer AI et al (2014) Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Delta32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 111:9591–9596

Zhen S, Hua L, Liu YH et al (2015) Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther 22:404–412